Bicuspid Aortic Valve DiseaseBAVConNCT01980797
International Bicuspid Aortic Valve Consortium (BAVCon)
An observational study of Bicuspid Aortic Valve Disease and Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve, run by Boston University at 12 sites in 5 countries.
Trial summary
Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population. In young adults, it is generally a benign abnormality; but in older adults it is associated with thoracic aortic aneurysm or dissection in 20-30% of those with BAV. Read more about this study
- Who is it for?
- Ages 8 to 90 years
- Conditions the study is for
- Bicuspid Aortic Valve Disease, Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve
- How many people
- 6,464 participants
- Where
- 12 sitesin 5 countries
- Study dates
- Nov 2013to Nov 2028
- How long will I take part?
- 20 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 90 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with and without bicuspid aortic valves disease
Who may be able to join
- Patients diagnosed as having a bicuspid aortic valve
- All ages ≥8 years
- Able to provide fully informed consent
Who cannot join
- None
Trial locations and contacts
12 sites in 5 countries.
12 sites in 5 countries
United States5 sites
University of Michigan
Ann Arbor, Michigan, 48109
Tufts Medical Center
Boston, Massachusetts, 02111
Boston Medical Center
Boston, Massachusetts, 02218
University of Texas Health Science Center at Houston
Houston, Texas, 77030
Mayo Clinic
Rochester, Minnesota, 55905
Italy4 sites
Monaldi Hospital
Naples, 80100
Second University of Naples
Naples, 80131
University of Salerno
Salerno, 36-83023
Istituto Policlinico San Donato
San Donato Milanese, Milan, 20097
About this study
Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population. In young adults, it is generally a benign abnormality; but in older adults it is associated with thoracic aortic aneurysm or dissection in 20-30% of those with BAV. BAV is strongly associated with early development of aortic valve calcification or incompetence in >50% of BAV patients, and accounts for ~40% of the >30,000 aortic valve replacements (AVR) performed in the US each year. Yet, we know little of the etiology, cellular events and modifiers of progression of BAV to calcific aortic valve disease and we still do not understand the genetic cause(s) of BAV despite evidence for its high heritability.
The Specific Aims of this study are:
Read more
- To identify the genetic causes of bicuspid aortic valve disease and its associated thoracic aortic disease.
- To identify potential pathways to predict the clinical course of BAV disease and for treating human BAV disease.
To achieve these aims, we have created the International Bicuspid Aortic Valve Consortium (BAVCon), a consortium of institutions with cohorts of BAV patients and the expertise to fulfill the performance of these aims.
Read the detailed description
The International Bicuspid Aortic Valve Consortium (BAVCon) Registry is the data collection arm of the International Bicuspid Aortic Valve Consortium, a 16 institution international consortium of investigators with interests in the genetics, molecular biology, imaging, surgery and natural history of bicuspid aortic valve disease.
The BAVCon Registry is a longitudinal cohort study, which is observational by design. The cohort will consist of patients with BAV. Consideration will be given to eventual inclusion of a disease-free control or comparison group. The study will compare genetic risk factors, cross-sectional and longitudinal data on risk factors related to the diagnosis, treatment and outcomes among groups of enrolled patients. As part of the natural course of clinical care, the patients and their physicians will determine the approach to treatment and the study will record the observed related outcomes. The study will not attempt to interfere with the outcomes through any type of planned intervention; therefore, there are no anticipated adverse events as a result of study participation.
Study Design
The Registry is designed to capture information on patients with bicuspid aortic valve disease. The BAVCon Registry population will be comprised of patients from sixteen BAVCon Clinical Centers. The participating BAVCon Clinical Centers are:
- Boston University School of Medicine, Boston (Dr. Simon Body, Consortium PI)
- GenTAC Consortium (Dr. Kim Eagle, PI)
- Hospital Vall d'Hebron, Barcelona, Spain (Dr. Arturo Evangelista, PI)
- Monaldi Hospital, Naples, Italy (Dr. Giuseppe Limongelli, PI)
- Mayo Clinic, Rochester (Dr. Hector Michelena, PI)
- Oxford University, Oxford, England (Dr. Malenka Bissell, PI)
- San Donato Hospital IRCCS, Milan, Italy (PI: Dr. Alessandro Frigiola)
- Tufts University, Boston (Dr. Gordon Huggins, PI)
- Université Laval, Quebec (Dr. Yohan Bossé, PI)
- University of Michigan, Ann Arbor (Dr. Bo Yang, PI)
- University of Salerno, Salerno, Italy (Dr. Eduardo Bossone, PI)
- University of Texas Medical School, Houston (Dr. Dianna Milewicz, PI) One center with specific expertise, but not enrolling patients, is University of Ottawa (Dr. Mona Nemer, PI).
The data supplied by each participating center are collected from the following sources:
Patient interview or questionnaire Hospital medical records Surgical records Imaging studies
Enrollment Information about the Registry will be disseminated to potential study subjects using a number of sources. The principal means of enrollment will be from the Cardiology and Surgical Clinics of each Hospital. In addition, collaborations with the patient advocacy groups such as the Bicuspid Aortic Valve Foundation. These organizations have well established resources for providing information to patients such as websites, newsletters, and national conferences. A recruitment brochure has been developed to explain the goals and basic procedures of the Registry. Finally, the study website, http://www.bavcon.org, will inform potential subjects about the Registry. All recruitment materials will be approved by the DCC and BCC IRBs, as appropriate, prior to dissemination.
BCC study staff will identify eligible patients using the eligibility criteria developed and approved by the Steering Committee. They will both screen their current patient population as well as identify new patients that attend the clinic. Eligible patients will be solicited during clinic visits according to protocols approved by the local IRB.
Initially, a care provider will introduce the Registry to the patient or the parent or guardian of the patient, and ask if they are interested in talking further with the research coordinator. If the patient (or parent or guardian) agrees, the research coordinator will meet with the patient for a more comprehensive explanation of the Registry. If there is continued agreement, the research coordinator will proceed with the consent and enrollment process. Signed informed consent will be obtained prior to any data or sample collection. Patients will receive a hard-copy of the consent form to keep. Patients will be able to ask questions at any time. One parent or guardian may provide signed consent for a minor child or other person with a physical or mental condition that prevents them from doing so themselves. Literacy in the native language of the country (English and Spanish in the USA) will be required of the consenting patient or parent/guardian. Child assent will be obtained from children at least 8 years of age, or as determined by the local IRB. Across all the sites, we anticipate total enrollment of up to 10,000 patients.
Eligibility Criteria
Inclusion criteria for entry into the Registry are:
- Patients diagnosed with bicuspid aortic valve
- All ages ≥8 years
- Able to provide fully informed consent
Local Site Restrictions Some sites will not be collecting tissue from patients, therefore information on tissue collection will be absent. Some sites do not routinely perform CT or MRI on their patients, so these data will also be absent.
- Conditions
- Bicuspid Aortic Valve Disease, Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve
- Keywords
- Bicuspid aortic valve disease, Thoracic aortic disease, Genetics, Echocardiography, Cardiac CT, Cardiac MRI
- Medical subject headings
- Bicuspid Aortic Valve Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Bicuspid aortic valve disease | Group/Cohort Label - Bicuspid aortic valve Group/Cohort Description - * Patients diagnosed with bicuspid aortic valve * All ages ≥8 years * Able to provide fully informed consent | |
| Tricuspid aortic valve control patients | Group/Cohort Label - Tricuspid aortic valve control patients Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched. * Patients not diagnosed with bicuspid aortic valve * All ages ≥8 years * Able to provide fully informed consent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bicuspid aortic valve disease
The first specific aim is to identify the genetic causes of bicuspid aortic valve disease.
Measured: 10 years
Secondary outcomes (1)
The development of thoracic aortic disease in patients with bicuspid aortic valve disease
The second specific aim is to identify genetic and non-genetic factors to cause thoracic aortic disease in BAV patients.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Nov 2013 (estimated)
- Study startNov 2013
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bicuspid Aortic Valve DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6,464 participants (actual)
- Target duration
- 20 Years
Sponsor and investigators
- Lead sponsor
- Boston University
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Simon C. Body, MD, MPH, Principal investigator, Boston University School of Medicine, Anesthesiology Department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01980797
- Sponsor's protocol ID
- H-39760
- Other IDs
- 1R21HL150373-01
- Acronym
- BAVCon
- Status last verified
- Mar 2026
- First submitted
- 5 Nov 2013
- Last updated
- 1 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- International Bicuspid Aortic Valve Consortium (BAVCon)
- ClinicalTrials.gov ID
- NCT01980797
- Acronym / sponsor ID
- BAVCon / H-39760
- Conditions
- Bicuspid Aortic Valve Disease, Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve
- Keywords
- Bicuspid aortic valve disease, Thoracic aortic disease, Genetics, Echocardiography, Cardiac CT, Cardiac MRI
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 6,464 participants (actual)
- Lead sponsor
- Boston UniversityUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Nov 2013 (actual)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 11 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population. In young adults, it is generally a benign abnormality; but in older adults it is associated with thoracic aortic aneurysm or dissection in 20-30% of those with BAV. BAV is strongly associated with early development of aortic valve calcification or incompetence in >50% of BAV patients, and accounts for ~40% of the >30,000 aortic valve replacements (AVR) performed in the US each year. Yet, we know little of the etiology, cellular events and modifiers of progression of BAV to calcific aortic valve disease and we still do not understand the genetic cause(s) of BAV despite evidence for its high heritability.
The Specific Aims of this study are:
- To identify the genetic causes of bicuspid aortic valve disease and its associated thoracic aortic disease.
- To identify potential pathways to predict the clinical course of BAV disease and for treating human BAV disease.
To achieve these aims, we have created the International Bicuspid Aortic Valve Consortium (BAVCon), a consortium of institutions with cohorts of BAV patients and the expertise to fulfill the performance of these aims.
Detailed description
The International Bicuspid Aortic Valve Consortium (BAVCon) Registry is the data collection arm of the International Bicuspid Aortic Valve Consortium, a 16 institution international consortium of investigators with interests in the genetics, molecular biology, imaging, surgery and natural history of bicuspid aortic valve disease.
The BAVCon Registry is a longitudinal cohort study, which is observational by design. The cohort will consist of patients with BAV. Consideration will be given to eventual inclusion of a disease-free control or comparison group. The study will compare genetic risk factors, cross-sectional and longitudinal data on risk factors related to the diagnosis, treatment and outcomes among groups of enrolled patients. As part of the natural course of clinical care, the patients and their physicians will determine the approach to treatment and the study will record the observed related outcomes. The study will not attempt to interfere with the outcomes through any type of planned intervention; therefore, there are no anticipated adverse events as a result of study participation.
Study Design
The Registry is designed to capture information on patients with bicuspid aortic valve disease. The BAVCon Registry population will be comprised of patients from sixteen BAVCon Clinical Centers. The participating BAVCon Clinical Centers are:
- Boston University School of Medicine, Boston (Dr. Simon Body, Consortium PI)
- GenTAC Consortium (Dr. Kim Eagle, PI)
- Hospital Vall d'Hebron, Barcelona, Spain (Dr. Arturo Evangelista, PI)
- Monaldi Hospital, Naples, Italy (Dr. Giuseppe Limongelli, PI)
- Mayo Clinic, Rochester (Dr. Hector Michelena, PI)
- Oxford University, Oxford, England (Dr. Malenka Bissell, PI)
- San Donato Hospital IRCCS, Milan, Italy (PI: Dr. Alessandro Frigiola)
- Tufts University, Boston (Dr. Gordon Huggins, PI)
- Université Laval, Quebec (Dr. Yohan Bossé, PI)
- University of Michigan, Ann Arbor (Dr. Bo Yang, PI)
- University of Salerno, Salerno, Italy (Dr. Eduardo Bossone, PI)
- University of Texas Medical School, Houston (Dr. Dianna Milewicz, PI) One center with specific expertise, but not enrolling patients, is University of Ottawa (Dr. Mona Nemer, PI).
The data supplied by each participating center are collected from the following sources:
Patient interview or questionnaire Hospital medical records Surgical records Imaging studies
Enrollment Information about the Registry will be disseminated to potential study subjects using a number of sources. The principal means of enrollment will be from the Cardiology and Surgical Clinics of each Hospital. In addition, collaborations with the patient advocacy groups such as the Bicuspid Aortic Valve Foundation. These organizations have well established resources for providing information to patients such as websites, newsletters, and national conferences. A recruitment brochure has been developed to explain the goals and basic procedures of the Registry. Finally, the study website, http://www.bavcon.org, will inform potential subjects about the Registry. All recruitment materials will be approved by the DCC and BCC IRBs, as appropriate, prior to dissemination.
BCC study staff will identify eligible patients using the eligibility criteria developed and approved by the Steering Committee. They will both screen their current patient population as well as identify new patients that attend the clinic. Eligible patients will be solicited during clinic visits according to protocols approved by the local IRB.
Initially, a care provider will introduce the Registry to the patient or the parent or guardian of the patient, and ask if they are interested in talking further with the research coordinator. If the patient (or parent or guardian) agrees, the research coordinator will meet with the patient for a more comprehensive explanation of the Registry. If there is continued agreement, the research coordinator will proceed with the consent and enrollment process. Signed informed consent will be obtained prior to any data or sample collection. Patients will receive a hard-copy of the consent form to keep. Patients will be able to ask questions at any time. One parent or guardian may provide signed consent for a minor child or other person with a physical or mental condition that prevents them from doing so themselves. Literacy in the native language of the country (English and Spanish in the USA) will be required of the consenting patient or parent/guardian. Child assent will be obtained from children at least 8 years of age, or as determined by the local IRB. Across all the sites, we anticipate total enrollment of up to 10,000 patients.
Eligibility Criteria
Inclusion criteria for entry into the Registry are:
- Patients diagnosed with bicuspid aortic valve
- All ages ≥8 years
- Able to provide fully informed consent
Local Site Restrictions Some sites will not be collecting tissue from patients, therefore information on tissue collection will be absent. Some sites do not routinely perform CT or MRI on their patients, so these data will also be absent.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 20 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bicuspid aortic valve disease | – | –Group/Cohort Label - Bicuspid aortic valve Group/Cohort Description - * Patients diagnosed with bicuspid aortic valve * All ages ≥8 years * Able to provide fully informed consent |
| Tricuspid aortic valve control patients | – | –Group/Cohort Label - Tricuspid aortic valve control patients Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched. * Patients not diagnosed with bicuspid aortic valve * All ages ≥8 years * Able to provide fully informed consent |
Who may qualify
- Ages
- 8 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with and without bicuspid aortic valves disease
Key inclusion criteria (3 listed)
- Patients diagnosed as having a bicuspid aortic valve
- All ages ≥8 years
- Able to provide fully informed consent
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Bicuspid aortic valve disease
Time frame: 10 years
The first specific aim is to identify the genetic causes of bicuspid aortic valve disease.
1 secondary outcome
The development of thoracic aortic disease in patients with bicuspid aortic valve disease
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
Related trials for Bicuspid Aortic Valve Disease
Enrolling by invitationObservational study
Bicuspid Aortic Valve (BAV) Registry
Bicuspid Aortic Valve
Recruiting
TAVR vs SAVR in Severe Bicuspid Aortic Stenosis
Bicuspid Aortic Valve Disease
RecruitingObservational study
Nordic Consortium for Acute Type A Aortic Dissection-2
Aortic Dissection
RecruitingObservational study
Follow-up of a Cohort of Patients With Aortic Valve Bicuspidia
Aortic Valve, Bicuspid
Active, not recruitingObservational study
Identification of Genetic Causes of Calcific Aortic Valve Disease
Calcific Aortic Stenosis, Calcific Aortic Stenosis - Bicuspid Valve
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Simon C. Body, MD, MPH principal investigator
Boston University School of Medicine, Anesthesiology Department
12 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bicuspid Aortic Valve Disease and Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve, run by Boston University at 12 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in United States, Italy, Canada, Spain, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bicuspid aortic valve disease (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026; AzTrials last refreshed its copy on 30 Oct 2026.